Enzo Biochem (NYSE:ENZ) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note released on Wednesday morning. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Trading Down 1.9 %

Enzo Biochem stock opened at $0.73 on Wednesday. Enzo Biochem has a fifty-two week low of $0.68 and a fifty-two week high of $1.50. The firm has a 50 day moving average price of $1.04 and a 200 day moving average price of $1.09.

Enzo Biochem (NYSE:ENZ) last issued its quarterly earnings data on Monday, December 16th. The medical research company reported ($0.05) earnings per share for the quarter. Enzo Biochem had a negative net margin of 81.73% and a negative return on equity of 11.84%.

Enzo Biochem Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Stockholders of record on Friday, November 15th were given a dividend of $0.10 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.40 annualized dividend and a dividend yield of 55.03%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. BBR Partners LLC purchased a new position in Enzo Biochem in the 3rd quarter valued at approximately $112,000. Renaissance Technologies LLC raised its stake in shares of Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after acquiring an additional 64,417 shares in the last quarter. XTX Topco Ltd boosted its holdings in Enzo Biochem by 94.5% in the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 13,735 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after purchasing an additional 11,742 shares during the period. Institutional investors and hedge funds own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.